Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

Philogen announces new publication in Nature Chemistry

Jul 4, 2023 | 2023, Press Releases, Scientific

The study was conducted by scientists at Philochem AG, the wholly owned Swiss subsidiary company of the Philogen group. The paper can be accessed on the Nature Chemistry website at the following link. Nat_chem_280223_press_release

Philogen Announces Clinical Trial Collaboration with MSD

Jun 1, 2023 | 2023, Press Releases, Scientific

Nidlegy™_CTCSA_Merck_Press_Release_ENG

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

May 26, 2023 | 2023, Press Releases, Scientific

230524_Philogen_STM_Press_Release

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Mar 28, 2023 | 2023, Press Releases, Scientific

The collaboration has focused on the use of Google’s Machine Learning models combined with Philochem’s DNA-Encoded Chemical Libraries. The research activity promises to have a direct impact on the discovery of novel tumor-targeting small organic ligands with broad...

Cell Press highlights the work of Philochem’s industrial Ph.D student

Feb 9, 2023 | 2023, Press Releases, Scientific

We are delighted to share the exciting journey of one of our talented PhD students Sara Puglioli, which has recently been covered in a CHEM article (Cell Press). Over the last years, Philochem AG has established industrial Ph.D. programs in collaboration with several...

Philogen publishes a new study in Pharmaceutics

Feb 2, 2023 | 2023, Press Releases, Scientific

Philogen announces the publication of a study in the peer-reviewed journal “Pharmaceutics” describing the development and the in vitro/vivo characterization of a novel interferon-gamma (IFNg) based antibody fusion protein. The paper can be accessed from the...
« Older Entries

Recent Posts

  • Fighting Cancer, the Italian Chemical Society Award to Dario Neri, CEO of Philogen
  • 18 settembre 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 11 settembre 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • Philogen kindly invites you to attend a virtual briefing for analysts on 2 October 2023 to discuss Company’s Half Year 2023 Results
  • 04 settembre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it